Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01195662 · ClinicalTrials.gov registry record · Phase 3
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,245
- Enrollment target
NCT01195662 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 2,245 participants.
The verdict
NCT01195662, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,245 participants
- Enrollment target
Study Summary
The purpose of this study is to learn if BMS-512148 (Dapagliflozin), after 12 weeks, can improve (decrease) blood pressure in patients with type 2 diabetes with uncontrolled hypertension who are on an Angiotensin-converting enzyme inhibitor (ACEI) or an Angiotensin Receptor Blocker (ARB).The safety of this treatment will also be studied
Interventions
- DRUG Dapagliflozin
- DRUG Placebo matching Dapagliflozin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,245 participants |
| Start Date | 2010-10 |
| Est. Completion | 2013-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01195662
The ClinicalTrials.gov registry entry for NCT01195662 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2,245 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Dapagliflozin is the first listed.
NCT01195662 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01195662 about?
NCT01195662 is a clinical study titled "A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication". The purpose of this study is to learn if BMS-512148 (Dapagliflozin), after 12 weeks, can improve (decrease) blood pressure in patients with type 2 diabetes with uncontrolled hypertension who are on an Angiotensin-converting enzyme inhibitor (ACEI) or an Angiotensin Receptor Blocker (ARB).The safety ...
What is the current status of trial NCT01195662?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,245 participants. The study started on 2010-10. Estimated completion is 2013-02.
What interventions are being tested in trial NCT01195662?
The interventions under investigation include: Dapagliflozin (DRUG), Placebo matching Dapagliflozin (DRUG).
Who is sponsoring clinical trial NCT01195662?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.